New clinical trial results reveal gedatolisib significantly improves progression-free survival in advanced HR+/HER2– breast ...

Gedatolisib combined with Faslodex and Ibrance improved progression-free survival in patients with advanced breast cancer ...

A two-drug combination for treating advanced kidney cancer has shown sustained and durable clinical benefit in more than five ...

Lantern Pharma has completed targeted enrolment for its multi-centre Phase II HARMONIC clinical trial of a disulfide small ...

Celcuity recently released positive results from its phase 3 VIKTORIA-1 trial, and is raising both debt and shares. Read what ...

Researchers at Sylvester Comprehensive Cancer Center reveal how body composition analysis predicts treatment response in ...

Trial data showed the drug dramatically reduced cancer progression risk in certain patients, supporting Celcuity’s plans to ...

Jaypirca led to better response rates than Imbruvica in some previously treated patients with chronic lymphocytic leukemia or ...

The COMPASSION-16 trial by Xiaohua Wu and colleagues addresses a crucial need in the management of advanced cervical cancer by evaluating cadonilimab, a novel bispecific antibody targeting PD-1 and ...

The analysis of FDA-approved next-in-class drugs also found that, among RCTs with head-to-head trials, fewer than 1 in 4 of ...

Celcuity shares jump as gedatolisib shows strong efficacy in HR+/HER2- breast cancer Phase 3 trial, with FDA filing expected ...

Cardiff Oncology has reported updated results from its phase 2 colorectal cancer trial, laying out data that it believes can ...